SUPPLEMENTARY INFORMATION

Similar documents
Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

BWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space

Supplementary results

of TERT, MLL4, CCNE1, SENP5, and ROCK1 on tumor development were discussed.

Role of FISH in Hematological Cancers

Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the

Aliccia Bollig-Fischer, PhD Department of Oncology, Wayne State University Associate Director Genomics Core Molecular Therapeutics Program Karmanos

Genomic structural variation

Supplementary Information

Chromothripsis: A New Mechanism For Tumorigenesis? i Fellow s Conference Cheryl Carlson 6/10/2011

Supplementary Figure 1. Schematic diagram of o2n-seq. Double-stranded DNA was sheared, end-repaired, and underwent A-tailing by standard protocols.

RNA SEQUENCING AND DATA ANALYSIS

Nature Structural & Molecular Biology: doi: /nsmb.2419

Nature Immunology: doi: /ni.3412

Relationship between genomic features and distributions of RS1 and RS3 rearrangements in breast cancer genomes.

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010

p.r623c p.p976l p.d2847fs p.t2671 p.d2847fs p.r2922w p.r2370h p.c1201y p.a868v p.s952* RING_C BP PHD Cbp HAT_KAT11

SALSA MLPA probemix P315-B1 EGFR

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Supplemental Data. Integrating omics and alternative splicing i reveals insights i into grape response to high temperature

TCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations.

Supplementary Figure 1

MODULE 4: SPLICING. Removal of introns from messenger RNA by splicing

Chromosome Structure & Recombination

MRC-Holland MLPA. Description version 08; 30 March 2015

Prevalence of HPV-16 genomic variant carrying a 63-bp duplicated sequence within the E1 gene in Slovenian women

CNV Detection and Interpretation in Genomic Data

Nature Structural & Molecular Biology: doi: /nsmb Supplementary Figure 1

MRC-Holland MLPA. Description version 12; 13 January 2017

Structural Variation and Medical Genomics

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.

Conditional and reversible disruption of essential herpesvirus protein functions

MRC-Holland MLPA. Description version 14; 28 September 2016

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Variations in Chromosome Structure & Function. Ch. 8

Supplementary Appendix

Generating Spontaneous Copy Number Variants (CNVs) Jennifer Freeman Assistant Professor of Toxicology School of Health Sciences Purdue University

High Throughput Sequence (HTS) data analysis. Lei Zhou

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

MRC-Holland MLPA. Description version 07; 26 November 2015

Supplementary Information. Supplementary Figures

CNV detection. Introduction and detection in NGS data. G. Demidov 1,2. NGSchool2016. Centre for Genomic Regulation. CNV detection. G.

NGS in tissue and liquid biopsy

ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA

Circular RNAs (circrnas) act a stable mirna sponges

Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA

Origin of oncogenes? Oncogenes and Proto-oncogenes. Jekyll and Hyde. Oncogene hypothesis. Retroviral oncogenes and cell proto-oncogenes

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis

Chromosomal Aberrations

Molecular Diagnosis. Nucleic acid based testing in Oncology

MRC-Holland MLPA. Description version 06; 23 December 2016

Nature Medicine: doi: /nm.4322

Nature Genetics: doi: /ng Supplementary Figure 1. Details of sequencing analysis.

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute

Supplemental Figure 1. Genes showing ectopic H3K9 dimethylation in this study are DNA hypermethylated in Lister et al. study.

Supplementary Figure 1: Attenuation of association signals after conditioning for the lead SNP. a) attenuation of association signal at the 9p22.

Introduction to Genetics

Hands-On Ten The BRCA1 Gene and Protein

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MARCH 13, 2012

Nature Genetics: doi: /ng Supplementary Figure 1. Somatic coding mutations identified by WES/WGS for 83 ATL cases.

2017 Diagnostic Slide Session Case 3

Chapter 4 Cellular Oncogenes ~ 4.6 -

Supplementary Figure 1. Spectrum and signatures of substitutions.

BIOL2005 WORKSHEET 2008

Rapid genomic screening of embryos using nanopore sequencing

Supplemental Figure S1A Notch1

Supplementary Tables. Supplementary Figures

SALSA MLPA KIT P060-B2 SMA

Molecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang

SALSA MLPA KIT P050-B2 CAH

CHAPTER 17 CHROMOSOME REARRANGEMENTS

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Understanding genetics, mutation and other details. Stanley F. Nelson, MD 6/29/18

RNA SEQUENCING AND DATA ANALYSIS

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

MRC-Holland MLPA. Description version 30; 06 June 2017

Problem Set 5 KEY

Chromosome Abnormalities

Supplementary Figure 1 Overall study design

Chronic myeloid leukemia (CML)

SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A

MRC-Holland MLPA. Description version 19;

MRC-Holland MLPA. Description version 29; 31 July 2015

Supplementary Figure 1: Tissue of Origin analysis on 152 cell lines. (a) Heatmap representation of the 30 Tissue scores for the 152 cell lines.

NEXT GENERATION SEQUENCING. R. Piazza (MD, PhD) Dept. of Medicine and Surgery, University of Milano-Bicocca

Antibodies and T Cell Receptor Genetics Generation of Antigen Receptor Diversity

Test Name Results Units Bio. Ref. Interval. Positive

Supplementary Fig. S1. Schematic diagram of minigenome segments.

Supplementary methods:

Variant Classification. Author: Mike Thiesen, Golden Helix, Inc.

MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.

How do living things Sexually Reproduce?

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Structural Chromosome Aberrations

Supplementary Figures

Supplementary note: Comparison of deletion variants identified in this study and four earlier studies

Transcription:

doi: 1.138/nature8645 Physical coverage (x haploid genomes) 11 6.4 4.9 6.9 6.7 4.4 5.9 9.1 7.6 125 Neither end mapped One end mapped Chimaeras Correct Reads (million ns) 1 75 5 25 HCC1187 HCC1395 HCC1599 HCC1937 HCC1954 HCC2157 HCC2218 HCC38 HCC1143 Physical coverage (x haploid genomes) 64 6.4 57 5.7 42 4.2 57 5.7 63 6.3 38 3.8 53 5.3 6 11.4 78 7.8 63 6.3 48 4.8 69 6.9 68 6.8 66 6.6 125 Neither end mapped One end mapped Chimaeras Correct Reads (millions s) 1 75 5 25 PD3664a PD3666a PD3668a PD367a PD3672a PD3688a PD369a PD3695a PD3665a PD3667a PD3669a PD3671a PD3687a PD3689a PD3693a Supplementary Figure 1 Haploid physical coverage of breast cancer samples. Physical coverage indicates the number of DNA fragments of which both ends have been sequenced that on average overlie any position in the genome. 1

doi: 1.138/nature8645 HCC2157 HCC1395 HCC1954 HCC1187 HCC1937 HCC1143 HCC2218 PD3667a PD3671a PD3689a PD3664a PD3668a PD3672a PD369a PD3669a PD3687a PD3665a PD3693a SI Guide Supplementary Figure 1 Haploid physical coverage of breast cancer samples. Physical coverage indicates the number of DNA fragments of which both ends have been sequenced HCC1599 HCC38 overlie any position PD3666a that on average in the genome. PD367a PD3688a PD3695a Supplementary Figure 2 Genome wide circos plots of somatic rearrangements in all 24 breast cancers in the study. Supplementary Figure 3 NFIA-EHF, an expressed, in frame fusion gene caused by an interchromosomal rearrangement in breast cancer cell line HCC1937. (a) Across not in normal DNA; (b) RT-PCR of RNA between NFIA exon 2 and EHF exon 5 to confirm the presence of a chimeric expressed transcript; (c) Representative picture of dual colour FISH confirming a translocation in HCC1937. Red probe corresponds to BAC RP11364M11, chromosome 1: 61,64,196-61,228,554. Green probe corresponds to BAC RP11277N8, chromosome 11: 34,772,14-34,965,946. (d) Schematic diagram of the protein domains fused in the predicted NFIA/EHF fusion protein. Domains from NFIA are blue, domains from EHF are red (e) Sequence from RT-PCR product shown in (b) confirming NFIA exon 2 fused to EHF exon 5. Supplementary Figure 4 SLC26A6-PRKAR2A, an expressed, in-frame fusion gene generated by a tandem duplication in the breast cancer cell line HCC38. (a) Across not in normal DNA; (b) RT-PCR of RNA between SLC26A6 exon 17 and PRKAR2A exon 4 to confirm the presence of a chimeric expressed transcript; (c) Dual colour FISH confirming the 3p21.31 tandem duplication in HCC38. Green-labelled BAC RP11-148G2 is within the 2

doi: 1.138/nature8645 a bps T N 6 4 2 d NFIA (exons 1-2) EHF (exons 5-9) Genomic PCR b bps 3 2 T N CTF/NF1 MH 1 DNA ETS DNA RT-PCR e c Dual colour FISH exon 2 NFIA exon 5 EHF Supplementary Figure 3 NFIA-EHF, an expressed, in frame fusion gene caused by an interchromosomal rearrangement in breast cancer cell line HCC1937. (a) Across not in normal DNA; (b) RT-PCR of RNA between NFIA exon 2 and EHF exon 5 to confirm the presence of a chimeric expressed transcript; (c) Representative picture of dual colour FISH confirming a translocation in HCC1937. Red probe corresponds to BAC RP11-364M11, chromosome 1: 61,64,196-61,228,554. Green probe corresponds to BAC RP11-277N8, chromosome 11: 34,772,14-34,965,946. (d) Schematic diagram of the protein domains fused in the predicted NFIA/EHF fusion protein. Domains from NFIA are blue, domains from EHF are red (e) Sequence from RT-PCR product shown in (b) confirming NFIA exon 2 fused to EHF exon 5. 3

No of rearrangements doi: 1.138/nature8645 2 2 2 2 15 15 15 15 1 1 1 1 5 5 5 5 No of rearran ngements HCC2157 No of rearrange ements HCC1937 HCC1599 2 2 2 2 15 15 15 15 1 1 1 1 5 5 5 5 HCC1395 HCC1187 HCC1143 HCC38 2 2 2 2 15 15 15 15 1 1 1 1 5 5 5 5 15 1 5 HCC2218 2 SI Guide PD3664a PD3664 PD3665a PD3665 PD3666a PD3666 2 2 2 15 15 15 1 1 Supplementary Figure 1 Haploid physical coverage of breast cancer samples. 5 Physical 5 5 coverage indicates the number of DNA fragments of which both ends have been sequenced that on average overlie any position in the genome. PD3667a PD3668a PD3669a PD367a 1 1 1 Supplementary 1 Figure 3 NFIA-EHF, an expressed, in frame fusion gene caused 1 by an No of rearrange ements 15 Supplementary Figure 2 Genome wide circos plots of somatic rearrangements in all 24 2 2 2 breast cancers in the study. 15 15 15 2 No of rearranggements No of rearrangements HCC1954 2 5 15 1 5 interchromosomal5rearrangement in breast cancer cell line HCC1937. (a) 5 5 Across not in normal DNA; (b) RT-PCR of RNA between NFIA exon 2 and EHF exon 5 to confirm PD3671a PD3672a PD3687a PD3688a the presence of a chimeric expressed transcript; (c) Representative picture of dual colour 2 FISH confirming a translocation in HCC1937.2 Red probe corresponds to 2 BAC RP11-15 1: 61,64,196-61,228,554. 15Green probe corresponds to15 364M11, chromosome BAC RP11277N8, chromosome 11: 34,772,14-34,965,946. the protein 1 1 (d) Schematic diagram of1 domains fused in the predicted NFIA/EHF fusion protein. Domains from NFIA are blue, 5 5 5 domains from EHF are red (e) Sequence from RT-PCR product shown in (b) confirming NFIA exon 2 fused to EHF exon 5. PD3689a PD369a PD3693a PD3695a PD3689 PD369 PD3693 PD3695 Supplementary Figure 4 SLC26A6-PRKAR2A, an expressed, in-frame fusion gene generated by a tandem duplication in the breast cancer cell line HCC38. (a) Across not in normal DNA; (b) RT-PCR of RNA between SLC26A6 exon 17 and PRKAR2A exon 4 to confirm the presence of a chimeric expressed transcript; (c) Dual colour FISH confirming the 3p21.31 tandem duplication in HCC38. Green-labelled BAC RP11-148G2 is within the 4

doi: 1.138/nature8645 not in normal DNA; (b) RT-PCR of RNA between SLC26A6 exon 17 and PRKAR2A exon 4 to confirm the presence of a chimeric expressed transcript; (c) Dual colour FISH confirming the 3p21.31 tandem duplication in HCC38. Green-labelled BAC RP11-148G2 is within the tandem duplication. Red-labelled BAC RP11-527M1 is located ~3 Mb telomeric of the tandem duplication. (d) Schematic diagram of the protein domains in the predicted SLC26A6-PRKAR2A fusion protein. Domains from SLC26A6 are blue, domains from PRKAR2A are red. (e) Sequence from RT-PCR product shown in (b) confirming SLC26A6 exon 17 fused to PRKAR2A exon 4. 5

doi: 1.138/nature8645 a bps T N 6 4 2 d SLC26A6 (exons 1-17) PRKAR2A (exons 4-11) b bps 6 4 2 Genomic PCR T N Sulphate Transporter cnmp camp/cgmp Kinase cnmp RT PCR e c Dual colour FISH of 3p21.31 tandem duplication exon 17 exon 4 SLC26A6 PRKAR2A Supplementary Figure 5 Prevalence of architectures of rearrangements in all 24 breast cancers in the study: Deletion (dark blue), tandem duplication (red), inverted orientation (green), interchromosomal (light blue), breakpoint(s) within an amplicon (orange). 6

doi: 1.138/nature8645 No of rearrangements No of rearrangements No of rearrangements No of rearrangements No of rearrangements No of rearrangements 5 4 3 2 1 5 4 3 2 1 5 4 3 2 1 5 4 3 2 1 5 4 3 2 1 5 4 3 2 1 5 5 5 4 4 4 3 3 3 2 2 2 1 1 1 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 HCC2157 HCC1954 HCC1937 HCC1599 5 5 5 4 4 4 3 3 3 2 2 2 1 1 1 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 HCC1395 HCC1187 HCC1143 HCC38 5 5 5 4 4 4 3 3 3 2 2 2 1 1 1 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 HCC2218 PD3664a PD3665a PD3666a 5 5 5 4 4 4 3 3 3 2 2 2 1 1 1 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 PD3667a PD3668a PD3669a PD367a 5 5 4 5 4 3 4 3 3 2 2 2 1 1 1 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 PD3671a PD3672a PD3687a PD3688a 5 5 5 4 4 4 3 3 3 2 2 2 1 1 1 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 1 2 3 4 5 >5 PD3689a PD369a PD3693a PD3695a Supplementary Figure 6 Number of nucleotides of overlapping microhomology at rearrangement junctions in the 24 breast cancers. 7

doi: 1.138/nature8645 3 Number of rearrangements 25 2 15 1 5 1 2 3 4 5 6-2 >2 Non-templated sequence (bps) Supplementary Figure 7 Nucleotides of non-templated DNA sequence at rearrangement breakpoints in the 24 breast cancers. 8